Bridged heterocyclic compounds and methods of use
US9006234B2 · kind B2 · utility
17Cited by
21References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 2, 2012 |
| Grant date | Apr 14, 2015 |
| Priority date | — |
| Expiry date | Jul 18, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic[4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.